Sinovac Biotech has initiated clinical trials for its pandemic flu (H5N1) vaccine
Panflu. The vaccine was administered to the first six volunteers at the Beijing
Sino-Japan Friendship Hospital in Beijing, China.
Due to this vaccine's mature technology, China's State Food and Drug Administration has approved modification to fast-track the clinical trial process from three stages to only two stages. Stage I includes 120 healthy volunteers, aged 18 to 60, and is expected to take nine-months. Preliminary results should be available by the end of March 2006.